Ann Rhoads

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Innovatix LLC provides group purchasing and consulting services. It offers negotiated contract discounts for various product categories, including blood products, capital equipment, enteral nutrition products and equipment, foodservice distribution, supplies and equipment, medical supplies, laboratory services and IT equipment and supplies. The company was founded in 1993 and is headquartered in New York, NY.

Myriad Women's Health, Inc. provides pre-pregnancy genetic testing services. It operates as a medical technology company that gives people access to vital information about their bodies, including DNA analysis for family preparation, and inherited cancers. The firm offers genetic counseling over the phone and gives client direct access to a professional genetics expert who can interpret their report. The company was founded by Ramji Srinivasan, Eric A. Evans, Rishi Kacker and Balaji S. Srinivasan on October 24, 2007 and is headquartered in South San Francisco, CA.

Innovatix LLC provides group purchasing and consulting services. It offers negotiated contract discounts for various product categories, including blood products, capital equipment, enteral nutrition products and equipment, foodservice distribution, supplies and equipment, medical supplies, laboratory services and IT equipment and supplies. The company was founded in 1993 and is headquartered in New York, NY.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Myriad Women's Health, Inc. provides pre-pregnancy genetic testing services. It operates as a medical technology company that gives people access to vital information about their bodies, including DNA analysis for family preparation, and inherited cancers. The firm offers genetic counseling over the phone and gives client direct access to a professional genetics expert who can interpret their report. The company was founded by Ramji Srinivasan, Eric A. Evans, Rishi Kacker and Balaji S. Srinivasan on October 24, 2007 and is headquartered in South San Francisco, CA.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Myriad Women's Health, Inc. provides pre-pregnancy genetic testing services. It operates as a medical technology company that gives people access to vital information about their bodies, including DNA analysis for family preparation, and inherited cancers. The firm offers genetic counseling over the phone and gives client direct access to a professional genetics expert who can interpret their report. The company was founded by Ramji Srinivasan, Eric A. Evans, Rishi Kacker and Balaji S. Srinivasan on October 24, 2007 and is headquartered in South San Francisco, CA.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Myriad Women's Health, Inc. provides pre-pregnancy genetic testing services. It operates as a medical technology company that gives people access to vital information about their bodies, including DNA analysis for family preparation, and inherited cancers. The firm offers genetic counseling over the phone and gives client direct access to a professional genetics expert who can interpret their report. The company was founded by Ramji Srinivasan, Eric A. Evans, Rishi Kacker and Balaji S. Srinivasan on October 24, 2007 and is headquartered in South San Francisco, CA.

Myriad Women's Health, Inc. provides pre-pregnancy genetic testing services. It operates as a medical technology company that gives people access to vital information about their bodies, including DNA analysis for family preparation, and inherited cancers. The firm offers genetic counseling over the phone and gives client direct access to a professional genetics expert who can interpret their report. The company was founded by Ramji Srinivasan, Eric A. Evans, Rishi Kacker and Balaji S. Srinivasan on October 24, 2007 and is headquartered in South San Francisco, CA.